Steven I. Aronin

Fulcrum Therapeutics (United States) — United States

Medicine · Health Sciences

14h-index1.2kcitations52works2.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Urinary Tract Infections Management(18), Antibiotics Pharmacokinetics and Efficacy(15), Antibiotic Resistance in Bacteria(12), Pneumonia and Respiratory Infections(11), Bacterial Infections and Vaccines(11)

Publications52 total

P-784. Risk Factors for Treatment Failure in Patients with Uncomplicated Urinary Tract Infection
Open Forum Infectious Diseases·2026Open Access
P-1208. In Vitro Activity of Sulopenem and Comparator Agents Against U.S. Enterobacterales Clinical Isolates, SENTRY Antimicrobial Surveillance Program, 2023
Open Forum Infectious Diseases·2026Open Access
Sulopenem versus Amoxicillin/Clavulanate for the Treatment of Uncomplicated Urinary Tract Infection
NEJM Evidence·2025· 6 cited
In vitro activity of sulopenem and comparator agents against US Enterobacterales clinical isolates collected during the SENTRY antimicrobial surveillance program in 2023
Journal of Global Antimicrobial Resistance·2025· 2 citedOpen Access
Characterization of sulopenem antimicrobial activity using <i>in vitro</i> time-kill kinetics, synergy, post-antibiotic effect, and sub-inhibitory MIC effect methods against <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> isolates
Microbiology Spectrum·2025· 5 citedOpen Access
P-1574. Asymptomatic Bacteriuria Not a Predictor of Clinical Failure in Uncomplicated Urinary Tract Infections (uUTI): A Prospective Analysis of Women Treated for uUTI from the REASSURE Trial
Open Forum Infectious Diseases·2025Open Access
P-1106. Sulopenem is Efficacious in a Rabbit Model of Inhalational Anthrax
Open Forum Infectious Diseases·2025Open Access
P-1107. Oral Sulopenem/probenecid for Uncomplicated Urinary Tract Infections (uUTI): Results from the REASSURE Trial
Open Forum Infectious Diseases·2025· 2 citedOpen Access
A phase 3 randomized trial of sulopenem vs. ertapenem in patients with complicated intra-abdominal infections
Clinical Microbiology and Infection·2024· 10 citedOpen Access
2106. Desirability of Outcome Ranking (DOOR): Application to a Phase 3 Registrational Trial Evaluating Sulopenem for Patients with Complicated Intra-abdominal Infection (cIAI)
Open Forum Infectious Diseases·2023Open Access
2568. Characterization of Sulopenem Pharmacokinetics-Pharmacodynamics Using a One-Compartment <i>In Vitro</i> Infection Model
Open Forum Infectious Diseases·2023· 4 citedOpen Access
2569. Pharmacokinetic-Pharmacodynamic Evaluation of Sulopenem Using a Five-Day Hollow-Fiber <i>In Vitro</i> Infection Model
Open Forum Infectious Diseases·2023· 3 citedOpen Access
Sulopenem Disk Development, Quality Control Range, and MIC to Disk Result Correlation for <i>Enterobacterales</i> Isolates
Journal of Clinical Microbiology·2023Open Access
<i>In vitro</i> activity of sulopenem and comparator agents against Enterobacterales and anaerobic clinical isolates collected during the SENTRY Antimicrobial Surveillance Program
Journal of Antimicrobial Chemotherapy·2023· 10 citedOpen Access
Applying Desirability of Outcome Ranking End Points
Clinical Infectious Diseases·2023Open Access
Applying Desirability of Outcome Ranking End Point to Randomized Trial of Sulopenem for the Treatment of Complicated Urinary Tract Infections
Clinical Infectious Diseases·2023· 1 citedOpen Access
227. Impact of Asymptomatic Bacteriuria on Primary Efficacy Analyses in the Evaluation of Novel Antimicrobials for the Treatment of Patients with Urinary Tract Infection
Open Forum Infectious Diseases·2022Open Access
1724. Murine Efficacy Studies of Sulopenem Against <i>Bacillus anthracis</i>
Open Forum Infectious Diseases·2022Open Access
Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial
Clinical Infectious Diseases·2022· 35 citedOpen Access
Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial
Clinical Infectious Diseases·2022· 37 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Michael W. Dunne(20), Sailaja Puttagunta(20), Anita Das(8), Michael T. Zelasky(6), Vincent Quagliarello(5), Vikas Gupta(5), Michael D. Huband(5), Jayanti Gupta(5), Karthik Akinapelli(4), Majid Sadigh(4), Sandip Mukherjee(3), Jeffrey C. West(3), Elizabeth Cooney(3), Kalvin Yu(3), Janet A. Watts(3), Helen W. Boucher(3), Donna A. McMillan(2), Carol Y. Lin(2), Elie M. Ferneini(2), Jeanne Breen(2)